Akinsanya O Osibogun, Faisal Mohammed Shuaib, Christianah Mojisola Adeyeye, Adebayo Temitayo Onajole, Clara Ladi Ejembi, Mathilda Edmund Banwat, Kikelomo Ololade Wright, Abdullahi Mohammed, Omokhoa Adedayo Adeleye, Shuaib Jauro Yahya, Chigozie Ozoemena Ifeadike, Uchenna Unije Elemuwa, Bassey Ekposen Bassey, Esther O Oluwole, Olufemi Akinwunmi Erinoso
INTRODUCTION: In Nigeria, immunisation with coronavirus disease 2019 (COVID-19) vaccines commenced in March 2021. COVISHIELD from AstraZeneca (AZ), a viral vector vaccine, was the brand administered in the first phase of vaccinations for pre-determined eligible adults 18 years and above. As more brands of COVID-19 vaccines have been introduced in Nigeria, identifying effective and safe vaccine brands is essential to pharmacovigilance and public health. The current study assessed the safety of the AZ-AZD1222 (ChAdOx1) COVID-19 vaccine in adults during the first phase of the vaccination exercise in Nigeria...
2023: Nigerian Postgraduate Medical Journal